NASDAQ:MSLE Satellos Bioscience (MSLE) Stock Price, News & Analysis $8.35 -0.60 (-6.70%) Closing price 04:00 PM EasternExtended Trading$8.34 -0.01 (-0.12%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About Satellos Bioscience Stock (NASDAQ:MSLE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Satellos Bioscience alerts:Sign Up Key Stats Today's Range$8.11▼$8.9550-Day Range$5.62▼$9.7952-Week Range$4.64▼$13.39Volume95,834 shsAverage Volume89,879 shsMarket Capitalization$174.01 millionP/E RatioN/ADividend YieldN/APrice Target$19.75Consensus RatingModerate Buy Company Overview Satellos Bioscience Inc. is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc., formerly known as iCo Therapeutics Inc., is based in Toronto, Ontario. Read More Satellos Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreMSLE MarketRank™: Satellos Bioscience scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingSatellos Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSatellos Bioscience has a consensus price target of $19.75, representing about 136.5% upside from its current price of $8.35.Amount of Analyst CoverageSatellos Bioscience has only been the subject of 4 research reports in the past 90 days.Read more about Satellos Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Satellos Bioscience are expected to decrease in the coming year, from ($1.69) to ($1.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Satellos Bioscience is -5.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSatellos Bioscience has a P/B Ratio of 4.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.65% of the float of Satellos Bioscience has been sold short.Short Interest Ratio / Days to CoverSatellos Bioscience has a short interest ratio ("days to cover") of 1.74, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Satellos Bioscience has recently increased by 18.95%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSatellos Bioscience does not currently pay a dividend.Dividend GrowthSatellos Bioscience does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentSatellos Bioscience has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of companies.News Coverage This WeekMarketBeat has tracked 1 news article for Satellos Bioscience this week, compared to 3 articles on an average week.Search Interest1 people have searched for MSLE on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Satellos Bioscience to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Satellos Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders37.90% of the stock of Satellos Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsSatellos Bioscience has minimal institutional ownership at this time.Read more about Satellos Bioscience's insider trading history. Receive MSLE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Satellos Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MSLE Stock News HeadlinesSatellos Bioscience Inc. (NASDAQ:MSLE) Receives Average Recommendation of "Moderate Buy" from BrokeragesJuly 15, 2026 | americanbankingnews.comHC Wainwright Brokers Increase Earnings Estimates for MSLEJuly 13, 2026 | americanbankingnews.comI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had written off. The stock climbed more than 1,100% over the next 3-4 years, with some subscribers reporting gains of $141,000, $272,000, or more. He believes a similar setup is forming now around what he calls the 'Energy Cube' - a compact nuclear system roughly the size of a shipping container, capable of powering up to 1,000 homes with no emissions, 24 hours a day. Bill Gates, Jeff Bezos, Google, and Microsoft have all backed companies in this space. The Nuclear Regulatory Commission is expected to issue a key approval as early as August - the first of its kind for this technology class in over a decade.July 20 at 1:00 AM | Monument Traders Alliance (Ad)Satellos’ oral DMD drug improves arm movement after six months in Phase IIJuly 10, 2026 | msn.comSatellos Bioscience Duchenne drug candidate's interim data boosts confidenceJuly 8, 2026 | msn.comSatellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults ...July 8, 2026 | tmcnet.comGuggenheim Keeps Their Buy Rating on Satellos Bioscience (MSLE)July 8, 2026 | theglobeandmail.comSatellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular DystrophyJune 29, 2026 | markets.businessinsider.comSee More Headlines MSLE Stock Analysis - Frequently Asked Questions How have MSLE shares performed this year? Satellos Bioscience's stock was trading at $11.27 on February 12, 2026. Since then, MSLE shares have decreased by 25.9% and is now trading at $8.35. How were Satellos Bioscience's earnings last quarter? Satellos Bioscience Inc. (NASDAQ:MSLE) issued its earnings results on Friday, May, 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.02. How do I buy shares of Satellos Bioscience? Shares of MSLE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/15/2026Today7/20/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:MSLE CIK1421642 WebN/A Phone(905) 336-6128Fax604-602-9699EmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Satellos Bioscience$19.75 High Price Target$23.00 Low Price Target$18.00 Potential Upside/Downside+136.5%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$24.87 million Net MarginsN/A Pretax MarginN/A Return on Equity-63.10% Return on Assets-58.03% Debt Debt-to-Equity RatioN/A Current Ratio16.48 Quick Ratio16.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.80 per share Price / Book4.64Miscellaneous Outstanding Shares20,840,000Free Float12,940,000Market Cap$174.01 million OptionableN/A Beta1.53 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:MSLE) was last updated on 7/20/2026 by MarketBeat.com Staff. From Our PartnersSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredTrump’s emergency dollar resetBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...Porter & Company | SponsoredIt’s one of Trump’s biggest holdings. Do you own it?President Trump holds up to $5 million in shares of an AI company that just landed a nearly $10 billion Pentag...InvestorPlace | SponsoredWhen governments buy their own debt, gold miners moveOn April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Satellos Bioscience Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Satellos Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
